Ifinatamab Deruxtecan Shows Promising Response Rates in Extensive-Stage Small Cell Lung Cancer Trial

Daiichi Sankyo and Merck's ifinatamab deruxtecan demonstrated clinically meaningful response rates in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC). The trial showed a confirmed objective response rate of 48.2%, with a median duration of response of 5.3 months and a disease control rate of 87.6%. In a subset of patients receiving ifinatamab deruxtecan as a second-line treatment, a confirmed ORR of 56.3% was observed.